Corient Private Wealth
DTIL icon

Corient Private Wealth’s Precision BioSciences DTIL Stock Holding History

Corient Private Wealth’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.7K Buy
143,852
+123,852
+619% +$571K ﹤0.01% 2750
2025
Q4 		$83.2K Buy
20,000
+10,000
+100% +$56.8K ﹤0.01% 2657
2025
Q3 		$55.2K Sell
10,000
-91,206
-90% -$437K ﹤0.01% 2491
2025
Q2 		$425K Buy
+101,206
New +$499K ﹤0.01% 1790
2025
Q1 		– Sell
-20,203
Closed -$77 – 2327
2024
Q4 		$77 Buy
20,203
+6,431
+47% +$47K ﹤0.01% 2354
2024
Q3 		$123K Hold
13,772
– – ﹤0.01% 2300
2024
Q2 		$134K Buy
13,772
+1,891
+16% +$22.3K ﹤0.01% 2178
2024
Q1 		$161K Buy
11,881
+4,297
+57% +$52.6K ﹤0.01% 2132
2023
Q4 		$83K Buy
7,584
+5,279
+229% +$56.9K ﹤0.01% 2170
2023
Q3 		$23.6K Buy
2,305
+14
+0.6% +$215 ﹤0.01% 2107
2023
Q2 		$36.2K Sell
2,291
-14
-0.6% -$320 ﹤0.01% 2035
2023
Q1 		$52.1K Buy
2,305
+1,851
+408% +$61K ﹤0.01% 1936
2022
Q4 		$16.2K Buy
+454
New +$17.9K ﹤0.01% 1672

Other funds holding DTIL

OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Corient Private Wealth's DTIL Position: Q1 2026 in Review

Corient Private Wealth increased its Precision BioSciences (DTIL) stake by 619% in Q1 2026, buying an estimated $571K and bringing the position to 143,852 shares worth $55.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2750.

Corient Private Wealth first reported a position in DTIL in Q4 2022 and has held it in 13 quarters since. The position peaked at $425K in Q2 2025. 78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

  • Corient Private Wealth held 143,852 shares of Precision BioSciences worth $55.7K as of Q1 2026.
  • Corient Private Wealth bought 123,852 Precision BioSciences shares in Q1 2026, an estimated $571K.
  • Precision BioSciences made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #2750 holding.
  • Corient Private Wealth first reported a position in Precision BioSciences in Q4 2022 and has held it in 13 quarters since.
  • Corient Private Wealth's Precision BioSciences position peaked at $425K in Q2 2025.
  • 78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.